Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis
- DOI
- 10.1038/s41398-025-03556-4
- Published
- 2025-08-29
- Container
- Translational Psychiatry
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41398-025-03556-4,
title = {Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis},
author = {Anton L. V. Avanceña and Linh Vuong and James G. Kahn and Elliot Marseille},
year = {2025},
journal = {Translational Psychiatry},
doi = {10.1038/s41398-025-03556-4},
url = {https://doi.org/10.1038/s41398-025-03556-4}
}RIS
TY - JOUR TI - Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis AU - Anton L. V. Avanceña AU - Linh Vuong AU - James G. Kahn AU - Elliot Marseille PY - 2025 JO - Translational Psychiatry DO - 10.1038/s41398-025-03556-4 UR - https://doi.org/10.1038/s41398-025-03556-4 ER -
APA
Avanceña, A. L. V., Vuong, L., Kahn, J. G., & Marseille, E. (2025). Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis. Translational Psychiatry. https://doi.org/10.1038/s41398-025-03556-4
Source records
- crossref · retrieved 2026-09-26T11:40:13.936Z